News
Among patients with grade 1 (least aggressive) or grade 2 (more aggressive than grade 1) somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), the phase 3 COMPETE ...
This combination has “the potential to become a new standard first-line treatment” for well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors with poor prognostic factors ...
Appendix cancer is a rare but increasingly recognized malignancy, often discovered incidentally during surgery for presumed ...
A young university student whose repeated symptoms of stomachache, nausea, vomiting, and weight loss were dismissed by doctors as anxiety was ultimately diagnosed with deadly cancer. Bruna was told ...
A phase 3 trial establishes 177Lu-dotatate plus long-acting octreotide as a new first-line treatment for patients with high-grade gastroenteropancreatic neuroendocrine tumors.
A phase 1 trial combines immunotherapy and an oncolytic virus for high-grade neuroendocrine tumors, aiming to enroll 36 patients by 2030. The trial evaluates Opdivo, Yervoy, and Seneca Valley ...
This is a subset of neuroendocrine tumors that are low or intermediate grade. Because they start in hormone-producing cells, some lung neuroendocrine tumors can make hormone-like substances called ...
There are 3 grades of neuroendocrine tumours (NETs) – grade 1, 2 and 3a: Grade 1 cancers grow slowly. They are low grade. Grade 2 grow at a moderate pace (between 1 and 3). ... European Neuroendocrine ...
A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center. The new trial will test the novel combination of ...
SAN FRANCISCO -- Adding a radioligand to standard therapy almost tripled median progression-free survival (PFS) in untreated high-grade gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a ...
1. Exelixis announces U.S. FDA approval of Cabometyx (cabozantinib) for patients with previously treated advanced neuroendocrine tumors. News release. Exelixis. March 26, 2025. Accessed March 26 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results